CompletedPhase 4

Optimal Dosage of Acetazolamide for OSA Treatment

Belgium91 participantsStarted 2021-04-20

Plain-language summary

Acetazolamide, a carbonic anhydrase inhibitor, has received some attention as potential treatment for obstructive sleep apnea (OSA). It produces a metabolic acidosis by excreting bicarbonate, thereby stimulating baseline ventilation. Evidence suggests that acetazolamide primarily improves ventilatory control instability (expressed as loop gain), which is an important contributor to the pathophysiology of OSA. Few studies have assessed the efficacy of acetazolamide in patients with OSA. Since most of them had a small sample size and used different therapeutic dosages, clinical applications are currently limited. Therefore, this study aims to compare the effect of two acetazolamide dosages on the severity and pathophysiology of OSA.

Who can participate

Age range18 Years – 79 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * AHI between 15 and 65 events/hour * BMI \< 35 kg/m² Exclusion Criteria: * Craniofacial anomalies * Central sleep apnea (defined as central AHI \> 25% of total AHI) * Contra-indications related to acetazolamide treatment * Hypersensitivity to sulphonamides or acetazolamide * Renal impairment, electrolyte imbalances, and/or adrenocortical insufficiency * Clinically significant metabolic, hepatic, and/or hematological disease * Chronic obstructive pulmonary disease * Closed-angle glaucoma * Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorders, heart failure, or any other unstable major medical condition. * Intake of drugs that substantially stimulate or depress respiration, including benzodiazepines, opioids, theophylline, and pseudoephedrine * Inadequately treated sleep disorders other than OSA that would confound functional sleep assessment * Inability of the patient to understand and/or comply to the study procedures * Active psychiatric disease (psychotic illness, major depression, anxiety attacks, alcohol or drug abuse) * Pregnancy

What they're measuring

Apnea-hypopnea index (AHI)

Timeframe: 4 weeks

Trial details

NCT IDNCT04726982

SponsorUniversity Hospital, Antwerp

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-03-19